Save $30 on a Pro or Premium
account
<ASX Spectator>
Archive
Sponsorship
Newsletter
Contact
<AD>
IMM
2023
<LINK>
Immutep (ASX:IMM) - First patient dosed in chemotherapy-free triple combination Phase II study
Jul 29, 2023
